; (2) $500,000,000 for fiscal year 2020; (3) $500,000,000 for fiscal year 2021; (4) $500,000,000 for fiscal year 2022; (5) $500,000,000 for fiscal year 2023; (6) $500,000,000 for fiscal year 2024; (7) $500,000,000 for fiscal year 2025; (8) $500,000,000 for fiscal year 2026; (9) $500,000,000 for fiscal year 2027; and (10) $500,000,000 for fiscal year 2028. 3436. Additional funding for the National Institutes of Health There is authorized to be appropriated to the National Institute of Health for the purpose of conducting research on addiction and pain related to substance misuse, including research to develop overdose reversal drug products, non-addictive drug products for treating pain, and drug products used to treat substance use disorder— (1) $1,000,000,000 for fiscal year 2019; (2) $1,000,000,000 for fiscal year 2020; (3) $1,000,000,000 for fiscal year 2021; (4) $1,000,000,000 for fiscal year 2022; (5) $1,000,000,000 for fiscal year 2023; (6) $1,000,000,000 for fiscal year 2024; (7) $1,000,000,000 for fiscal year 2025; (8) $1,000,000,000 for fiscal year 2026; (9) $1,000,000,000 for fiscal year 2027